Targeting B cells in severe thrombotic thrombocytopenic purpura--a road to cure?
- PMID: 22179358
- PMCID: PMC3243898
- DOI: 10.1097/CCM.0b013e318232d2b6
Targeting B cells in severe thrombotic thrombocytopenic purpura--a road to cure?
Conflict of interest statement
The author has not disclosed any potential conflicts of interest.
Comment on
-
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.Crit Care Med. 2012 Jan;40(1):104-11. doi: 10.1097/CCM.0b013e31822e9d66. Crit Care Med. 2012. PMID: 21926591 Clinical Trial.
References
-
- George JN. Clinical practice. Thrombotic thrombocytopenic purpura. New Engl J Med. 2006;354(18):1927–1935. - PubMed
-
- Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New Eng J Med. 1991;325(6):393–397. - PubMed
-
- von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher. 2002;6(4):320–328. - PubMed
-
- Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Eng J Med. 2004;350(25):2572–2581. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
